10 Steps To Better Alzheimer’s Disease Research
 

To date, advances in improving the lives of patients suffering from the ravages of Alzheimer's Disease (AD) and related dementias have been hard won, but research is at a tipping point. This CRO shares their 40 years of knowledge in Alzheimer's Disease research with steps on how to improve processes.

Driving Patient Engagement In Alzheimer’s Disease Clinical Research To Achieve Trial Success
 

This article discusses best practices for developing and implementing a patient-centered approach to Alzheimer’s Disease clinical research. Using the right channels and messaging to speed recruitment and provide lasting engagement can improve study success rates.

Improving Screen Failure And Recruitment Rates In Alzheimer’s Disease Clinical Trials
 

Failures in Alzheimer's Disease (AD) clinical trials have been attributed to inadequate understanding of mechanisms of action, poor target engagement, poor study design, wrong stage of AD matched to a particular drug, limited statistical power of endpoint measures, and inclusion of ineligible participants. This article addresses methods to minimize screen failure rates and improve overall recruitment rates in these notoriously difficult-to-enroll trials.

Five Questions To Ask A Prospective Contract Research Organization
 

Historical relationships between sponsors and CROs in Alzheimer’s Disease research can be characterized as a predictable, slow, capacity-driven business model with primarily transactional exchanges. This eBook explores questions sponsors should consider of CROs to change the paradigm to an intuitive, strategic partnership that can help them stand out from the crowd and make their molecule a star.

Solutions
The Cure For The Common CRO
 

To be successful, your molecule deserves unparalleled experience in Alzheimer’s Disease clinical research. You need a research partner with an uncommon understanding of the complexities associated with evaluating patients with various phenotypes and the ability to implement specific design features to mitigate the risks and challenges specific to Alzheimer’s studies.